Clinical trial failures

Sponsor hub

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. clinical trial failures

Review 49 stopped clinical trials from Pfizer's Upjohn has merged with Mylan to form Viatris Inc., including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 8 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials49
Likely biological signals8
Shown below49

Dominant stop reasons

OTHER/UNKNOWN
22
OPERATIONAL
18
SAFETY
5
EFFICACY/FUTILITY
3
REGULATORY
1

Notable sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
49

Related phases

Phase III
20
Phase IV
19
Phase I
5
Phase II
4
Unknown
1

Crawlable stopped-trial records

Open Explore

Showing up to 49 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT02060487: Effects of Oral Sildenafil on Mortality in Adults With PAH

Phase IV Pulmonary Arterial Hypertension trial by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Stop reason: OPERATIONAL.

Study was terminated by Sponsor at recommendation of Data Monitoring Committee after completion of first interim analysis as primary objective was met.

NCT00343655: Evaluation of Atorvastatin Treatment on Carotid Plaque.

Phase III Cardiovascular Diseases trial by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Stop reason: OTHER/UNKNOWN.

The study was terminated on June 22, 2007 for inability to enroll patients within an appropriate timeframe. There were no efficacy/safety concerns.